Smith Drake J, Lin Levina J, Moon Heesung, Pham Alexander T, Wang Xi, Liu Siyuan, Ji Sunjong, Rezek Valerie, Shimizu Saki, Ruiz Marlene, Lam Jennifer, Janzen Deanna M, Memarzadeh Sanaz, Kohn Donald B, Zack Jerome A, Kitchen Scott G, An Dong Sung, Yang Lili
1 Department of Microbiology, Immunology and Molecular Genetics, University of California , Los Angeles, California.
2 Molecular Biology Interdepartmental PhD Program, University of California , Los Angeles, California.
Stem Cells Dev. 2016 Dec 15;25(24):1863-1873. doi: 10.1089/scd.2016.0193. Epub 2016 Oct 18.
The humanized bone marrow-liver-thymus (BLT) mouse model harbors a nearly complete human immune system, therefore providing a powerful tool to study human immunology and immunotherapy. However, its application is greatly limited by the restricted supply of human CD34 hematopoietic stem cells and fetal thymus tissues that are needed to generate these mice. The restriction is especially significant for the study of human immune systems with special genetic traits, such as certain human leukocyte antigen (HLA) haplotypes or monogene deficiencies. To circumvent this critical limitation, we have developed a method to quickly propagate established BLT mice. Through secondary transfer of bone marrow cells and human thymus implants from BLT mice into NSG (NOD/SCID/IL-2Rγ) recipient mice, we were able to expand one primary BLT mouse into a colony of 4-5 proBLT (propagated BLT) mice in 6-8 weeks. These proBLT mice reconstituted human immune cells, including T cells, at levels comparable to those of their primary BLT donor mouse. They also faithfully inherited the human immune cell genetic traits from their donor BLT mouse, such as the HLA-A2 haplotype that is of special interest for studying HLA-A2-restricted human T cell immunotherapies. Moreover, an EGFP reporter gene engineered into the human immune system was stably passed from BLT to proBLT mice, making proBLT mice suitable for studying human immune cell gene therapy. This method provides an opportunity to overcome a critical hurdle to utilizing the BLT humanized mouse model and enables its more widespread use as a valuable preclinical research tool.
人源化骨髓-肝脏-胸腺(BLT)小鼠模型拥有近乎完整的人类免疫系统,因此为研究人类免疫学和免疫疗法提供了一个强大的工具。然而,其应用受到生成这些小鼠所需的人类CD34造血干细胞和胎儿胸腺组织供应受限的极大限制。这种限制对于研究具有特殊遗传特征的人类免疫系统尤为显著,例如某些人类白细胞抗原(HLA)单倍型或单基因缺陷。为了克服这一关键限制,我们开发了一种快速繁殖已建立的BLT小鼠的方法。通过将骨髓细胞和人胸腺植入物从BLT小鼠二次转移到NSG(NOD/SCID/IL-2Rγ)受体小鼠中,我们能够在6-8周内将一只初代BLT小鼠扩展为一个由4-5只proBLT(繁殖的BLT)小鼠组成的群体。这些proBLT小鼠重建人类免疫细胞,包括T细胞,其水平与它们的初代BLT供体小鼠相当。它们还忠实地从供体BLT小鼠继承了人类免疫细胞遗传特征,例如对于研究HLA-A2限制性人类T细胞免疫疗法特别感兴趣的HLA-A2单倍型。此外,工程改造到人类免疫系统中的EGFP报告基因从BLT稳定地传递到proBLT小鼠,使得proBLT小鼠适合用于研究人类免疫细胞基因疗法。这种方法提供了一个机会来克服利用BLT人源化小鼠模型的一个关键障碍,并使其更广泛地用作有价值的临床前研究工具。